{"id":16522,"date":"2021-02-09T17:15:54","date_gmt":"2021-02-09T16:15:54","guid":{"rendered":"https:\/\/idibell.cat\/?p=16522"},"modified":"2021-02-10T08:37:32","modified_gmt":"2021-02-10T07:37:32","slug":"desxifren-els-mecanismes-implicats-en-lactivitat-antitumoral-despres-de-la-inhibicio-de-la-formacio-de-nous-ribosomes","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2021\/02\/desxifren-els-mecanismes-implicats-en-lactivitat-antitumoral-despres-de-la-inhibicio-de-la-formacio-de-nous-ribosomes\/","title":{"rendered":"Desxifren els mecanismes implicats en l’activitat antitumoral despr\u00e9s de la inhibici\u00f3 de la formaci\u00f3 de nous ribosomes"},"content":{"rendered":"

Els limfomes causats per afectacions de gen myc posseeixen una elevada depend\u00e8ncia de la formaci\u00f3 de nous ribosomes, la maquin\u00e0ria cel\u00b7lular responsable de la s\u00edntesi de prote\u00efnes. Aquests, com la majoria de c\u00e0ncers, tenen una taxa de creixement cel\u00b7lular elevada pel que necessiten l’aportaci\u00f3 de noves prote\u00efnes per mantenir-se. Aquesta alta depend\u00e8ncia converteix el proc\u00e9s de formaci\u00f3 de nous ribosomes en una diana terap\u00e8utica ideal<\/strong>.<\/p>\n

Estudis previs ja han demostrat que la inhibici\u00f3 de la formaci\u00f3 de nous ribosomes suposa una disminuci\u00f3 del creixement de les c\u00e8l\u00b7lules tumorals. No obstant aix\u00f2, el mecanisme pel qual aix\u00f2 passa segueix sent una inc\u00f2gnita.<\/p>\n

L’equip de Metabolisme i C\u00e0ncer de l’Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL<\/a>) liderat pels Drs. Joffrey Pelletier<\/strong> i George Thomas<\/strong> acaba de treure un article en el qual descriuen que: la inhibici\u00f3 de la formaci\u00f3 de nous ribosomes no nom\u00e9s comporta una disminuci\u00f3 de la s\u00edntesi de prote\u00efnes, i en conseq\u00fc\u00e8ncia una baixada en la proliferaci\u00f3 de les c\u00e8l\u00b7lules tumorals, sin\u00f3 que tamb\u00e9 promou la mort de les c\u00e8l\u00b7lules tumorals<\/strong>.<\/p>\n

Aix\u00ed mateix, l’estudi publicat avui a la revista Blood<\/em><\/a>, tamb\u00e9 demostra que l’activaci\u00f3 d’aquestes vies de mort \u00e9s el mecanisme d’acci\u00f3 utilitzat pel f\u00e0rmac quimioter\u00e0pic Actinomicina D<\/strong>. Aquest f\u00e0rmac, inicialment usat com a antibi\u00f2tic, inhibeix la formaci\u00f3 d’ARN ribosomal i per tant la formaci\u00f3 de noves de prote\u00efnes.<\/p>\n

En tots dos casos, la via de mort activada per les c\u00e8l\u00b7lules tumorals implica un dels supressors de tumors m\u00e9s importants, p53<\/strong>. A m\u00e9s, tamb\u00e9 participa MCL-1<\/strong>, una prote\u00efna essencial per a la superviv\u00e8ncia tumoral que ha despertat un gran inter\u00e8s com a diana terap\u00e8utica en els \u00faltims anys.<\/p>\n

Un detall interessant de l’estudi, com ens diu la Dra. Ana Domostegui<\/strong>, \u00e9s que nom\u00e9s alguns dels components que participen en la formaci\u00f3 de nous ribosomes a la vegada estan involucrats en l’activaci\u00f3 de la mort cel\u00b7lular programada en els limfomes dependents de myc. De la mateixa manera, l’Actinomicina D utilitza aquesta via, amb els mateixos components, per promoure la mort cel\u00b7lular i aix\u00ed aturar la progressi\u00f3 tumoral.<\/p>\n

\u00a0<\/strong><\/p>\n

Inhibir la formaci\u00f3 de ribosomes: \u00bfNova estrat\u00e8gia contra myc<\/em>?<\/h3>\n

 <\/p>\n

Myc<\/em> \u00e9s un gen que regula gran quantitat de processos cel\u00b7lulars: el creixement cel\u00b7lular, el cicle de divisi\u00f3, la s\u00edntesi de prote\u00efnes, etc. Tots, processos tamb\u00e9 dependents de la biog\u00e8nesi de ribosomes. La seva implicaci\u00f3 en processos tan importants explica per qu\u00e8 myc<\/em> es troba desregulat en el 70% dels c\u00e0ncers humans.<\/p>\n

D’altra banda, la desregulaci\u00f3 de myc<\/em> tamb\u00e9 pot ser un proc\u00e9s intr\u00ednsec de supressi\u00f3 de tumors, activant vies de mort cel\u00b7lular programada i senesc\u00e8ncia<\/strong>, Aquest paper de myc<\/em> fa que, per al desenvolupament de limfomes, o altres tipus de c\u00e0ncer, l’evasi\u00f3 d’aquest proc\u00e9s intr\u00ednsec sigui necessari perqu\u00e8 la malaltia es desenvolupi.<\/p>\n

“Fa anys que intentem inhibir myc, per\u00f2 fins ara no hav\u00edem tingut massa \u00e8xit<\/em>” ens comenta la Dra. Domostegui<\/strong>, primera autora del treball, i afegeix “la nostra estrat\u00e8gia consisteix a atacar un dels punts d\u00e8bils d’aquests tumors, la formaci\u00f3 de ribosomes, utilitzant l’Actinomicina D, un f\u00e0rmac aprovat des de fa anys, de manera que la possibilitat d’oferir un tractament a pacients amb aquests tipus de limfomes est\u00e0 molt a prop<\/em>. ”<\/p>\n

 <\/p>\n

Col\u00b7laboracions<\/h3>\n

 <\/p>\n

Aquest treball ha estat possible gr\u00e0cies a la col\u00b7laboraci\u00f3 de cient\u00edfics de centres com la Divisi\u00f3 d’Hematologia Oncol\u00f2gica de la Universitat de Cincinnati, la Universitat de Barcelona, l’Institut d’Investigacions Biom\u00e8diques Pi i Sunyer (IDIBAPS), l’Institut Catal\u00e0 d’Oncologia (ICO) , i el Centre de C\u00e0ncer Peter MacCallum i l’Institut d’Investigaci\u00f3 M\u00e8dica Walter and Eliza Hall tots dos de Melbourne, Austr\u00e0lia.<\/p>\n

 <\/p>\n

 <\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

\u00a0<\/em>L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Un grup de recerca de l’IDIBELL, ha publicat a la revista Blood els seus descobriments sobre els mecanismes cel\u00b7lulars responsables d’aturar el creixement tumoral al bloquejar la formaci\u00f3 de nous ribosomes.<\/p>\n","protected":false},"author":8,"featured_media":16523,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,408,447],"tags":[],"class_list":["post-16522","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-metabolisme-del-cancer","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell"],"publishpress_future_action":{"enabled":false,"date":"2025-01-25 10:27:20","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/16522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=16522"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/16522\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/16523"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=16522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=16522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=16522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}